This study, called LAYOVER, is looking at how well adding local ablative therapies (like Stereotactic Ablative Radiotherapy (SABR) or interventional radiology (IR) ablation therapy) to ongoing systemic (whole-body) treatment works for people with certain genitourinary cancers that are "oligo-progressive." This means the cancer has progressed in a limited number of spots. You might be able to join if you have prostate cancer, urothelial carcinoma (bladder cancer), or renal cell carcinoma (kidney cancer). The study aims to see if this approach helps control the disease for at least 3 months. The study plans to enroll 150 participants, but its current status is unclear.

Study design

This is a single-site, phase 2 pragmatic study that will enroll 150 participants. It is not specified if it is randomized or blinded.

What's involved

Participants will receive ablative local therapy in addition to their systemic therapy. You will be followed for up to 5 years after the ablative local therapy.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 5 years after receiving ablative local therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.